| Rufiji District | Kilombero/Ulanga Districts1 | Total (%) |
---|---|---|---|
Total suspected adverse drug events reported | 45 | 50 | 95 (100) |
Identified through active surveillance | 21 | 30 | 51 (53.7) |
Identified through passive surveillance | 24 | 20 | 44 (46.3) |
Number of cases successfully traced | 38 | 41 | 79 (83.2) |
Of the successfully traced cases: | 38 | 41 | N = 79 (100) |
Events associated with SP monotherapy | 20 | 33 | 53 (67.1) |
Events associated with AS/SP combination therapy | 13 | 0 | 13 (16.5) |
Events associated with AS monotherapy | 1 | 0 | 1 (1.3) |
Events outside DSS area (excluded) | 3 | 5 | 8 (10.0) |
Events unrelated to SP and/or AS (excluded) | 1 | 3 | 4 (5.0) |
Dominant symptoms reported for those included: | 34 | 33 | N = 67 (100) |
Body blisters and skin detachment | 7 | 11 | 18 (26.9) |
Body swelling, itching and urticarial rashes | 10 | 6 | 16 (23.9) |
Multiple lésions on mucus membranes | 6 | 7 | 13 (19.4) |
Facial edema, sore mouth/nose conjunctiva | 5 | 4 | 9 (13.4) |
Others1 | 6 | 5 | 11 (16.4) |
Deaths | |||
Deaths attributable to SP and/or AS caused ADR | 2 | 4 | 6 (8.9%) |